This page shows the latest Amarin news and features for those working in and with pharma, biotech and healthcare.
Amarin was hit again in September 2020, after the US Court of Appeals upheld the lower court’s ruling that invalidated the patents covering Vascepa. ... In a statement, Amarin said that it would be ‘reviewing its legal options’ following the US
is approved by FDA, prevent launch of generic versions of Vascepa,” said John Thero, CEO of Amarin. ... The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.
The outlook for Northsea looks positive given Amarin’s success with its own fish oil-derived drug Vascepa (icosapent ethyl). ... This blockbuster indication has Amarin “aggressively launching” Vascepa in the US, after the company estimated expected
Drug is on course for blockbuster sales. Amarin has been given an early Christmas present by the FDA – the approval of its fish oil-derived drug Vascepa to reduce the risk ... The expanded approval for Amarin’s only marketed product was odds on after
The European Medicines Agency (EMA) has started a review of Irish drugmaker Amarin’s fish oil-derived drug – sold as Vascepa in the US – setting up an approval next year. ... as Amarin starts to expand its salesforce for the drug from 400 to 800
We appreciate both the opportunity to present these results and the committee’s strong vote of confidence,” said John Thero, president and chief executive officer of Amarin. ... These gains also lend more credit to the ongoing speculation that
More from news
Approximately 11 fully matching, plus 5 partially matching documents found.
aureus and Shigellosis. Corporate acquisition. 190. Amarin/ Eddingpharm. VASCEPA (icosapent ethyl) - triglyceride level reduction.
All may not be plain sailing with this BASF strategy however given the promise of a crowded market place with the anticipated introduction of Amarin's Vascepa next year, to be
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Takes up newly-created chief commercial officer role. Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer. ... Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...